Ma Lijun, Hanson Robert L, Que Lorem N, Guo Yan, Kobes Sayuko, Bogardus Clifton, Baier Leslie J
Department of Health and HumanServices, Diabetes Molecular Genetics Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and KidneyDiseases, National Institutes of Health, Phoenix, Arizona, USA.
Diabetes. 2008 Nov;57(11):3156-60. doi: 10.2337/db07-1800. Epub 2008 Jul 22.
A prior genome-wide association (GWA) study in Pima Indians identified variants within PCLO that were associated with early-onset type 2 diabetes. PCLO encodes a presynaptic cytomatrix protein that functions as a Ca(2+) sensor that may be involved in insulin secretion and/or insulin action. Therefore, PCLO was analyzed as a candidate gene for type 2 diabetes.
Sequencing of PCLO identified four nonsynonymous variants and a 10-amino acid insertion. These variants, together with 100 additional variants identified by sequencing or chosen from databases, were genotyped for association analysis in the same 895 subjects analyzed in the prior GWA study (300 case subjects with diabetes onset at aged <25 years, 334 nondiabetic control subjects aged >45 years, and 261 discordant siblings of the case or control subjects for within-family analyses), as well as 415 nondiabetic Pima Indians who had been metabolically phenotyped for predictors of diabetes. Selected variants were further genotyped in a population-based sample of 3,501 Pima Indians.
Four variants were modestly associated with early-onset type 2 diabetes in both general and within-family analyses (P = 0.004-0.04, recessive model), where the diabetes risk allele was also nominally associated with a lower insulin-mediated glucose disposal rate (P = 0.009-0.14, recessive model) in nondiabetic Pima Indians. However, their association with diabetes in the population-based sample was weaker (P = 0.02-0.20, recessive model).
Variation within PCLO may have a modest effect on early-onset type 2 diabetes, possibly as a result of reduced insulin action, but has minimal, if any, impact on population-based risk for type 2 diabetes.
先前针对皮马印第安人的全基因组关联(GWA)研究确定了PCLO基因内与早发型2型糖尿病相关的变异。PCLO编码一种突触前细胞基质蛋白,其作为一种钙(Ca2+)传感器发挥作用,可能参与胰岛素分泌和/或胰岛素作用。因此,将PCLO作为2型糖尿病的候选基因进行分析。
对PCLO进行测序,发现了四个非同义变异和一个10个氨基酸的插入。这些变异,连同通过测序鉴定或从数据库中选取的另外100个变异,在先前GWA研究中分析的同一895名受试者(300名糖尿病发病年龄小于25岁的病例受试者、334名年龄大于45岁的非糖尿病对照受试者以及261名病例或对照受试者的不一致同胞用于家系内分析)以及415名已进行糖尿病预测代谢表型分析的非糖尿病皮马印第安人中进行基因分型以进行关联分析。在一个基于人群的3501名皮马印第安人样本中对选定的变异进一步进行基因分型。
在一般分析和家系内分析中,四个变异均与早发型2型糖尿病存在适度关联(P = 0.004 - 0.04,隐性模型),在非糖尿病皮马印第安人中,糖尿病风险等位基因在名义上也与较低的胰岛素介导的葡萄糖处置率相关(P = 0.009 - 0.14,隐性模型)。然而,它们在基于人群的样本中与糖尿病的关联较弱(P = 0.02 - 0.20,隐性模型)。
PCLO基因内的变异可能对早发型2型糖尿病有适度影响,可能是胰岛素作用降低的结果,但对基于人群的2型糖尿病风险影响极小(若有影响的话)。